publication venue for
- Impact of Laparotomy and Intraperitoneal Hyperthermic Instillation (LIHI) on the oxaliplatin pharmacokinetics after intravenous administration in Wistar rats.. 621-627. 2017
- Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02. 319-324. 2015
- Importance of standardizing the dose in hyperthermic intraperitoneal chemotherapy (HIPEC): a pharmacodynamic point of view.. 273-274. 2013
- Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma. 75-82. 2013
- Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. 883-890. 2013
- Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects. 1-10. 2008
- Semi-mechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. 2007
- Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib.. 681-691. 2006